Current therapeutic concepts in Peripartum cardiomyopathy

Current Pharmaceutical Design

Volumn 21, Issue 4, 2015, Pages 507-514

  Krejčí, Jan ^a   Poloczková, Hana ^a   Němec, Petr ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Aetiology; Diagnosis; Peripartum cardiomyopathy; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BROMOCRIPTINE; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; NITRIC ACID DERIVATIVE; PENTOXIFYLLINE;

ACUTE HEART FAILURE; AFRICAN; ANTICOAGULATION; APOPTOSIS; ARTICLE; ASSISTED CIRCULATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEVELOPED COUNTRY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DIURETIC THERAPY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXPERIMENTAL THERAPY; FATIGUE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMODYNAMIC PARAMETERS; HEMODYNAMIC STRESS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MEDIATOR RELEASE; MORTALITY; MYOCARDITIS; OXIDATIVE STRESS; PAROXYSMAL DYSPNEA; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SYSTOLIC HEART FAILURE; UNITED STATES; VIRUS INFECTION; CARDIOMYOPATHIES; DRUG EFFECTS; PERINATAL PERIOD;

CARDIOMYOPATHIES; HUMANS; PERIPARTUM PERIOD;

EID: 84925854042     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282104141204144035     Document Type: Article

References (77)

1. [1] Capriola M. Peripartum cardiomyopathy: a review. Int J Womens Health 2013; 5: 1-8.
2. [2] Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 2011; 58: 659-70.
3. [3] Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006; 97: 1765-8.
4. [4] Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors and outcomes. Obstet Gynecol 2011; 118: 583-91.
5. [5] Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368: 687-93.
6. [6] Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767-78.
7. [7] Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopthy. Heart 2011; 97: 1970-81.
8. [8] Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007; 118: 295-303.
9. [9] Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and comparison between early and late presentation. Circulation 2005; 111: 2050-5.
10. [10] Demakis JG, Rahimtoola SH. Peripartum Cardiomyopathy. Circulation 1971; 44: 964-8.
11. [11] Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999; 94: 311-6.
12. [12] Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270-6.
13. [13] Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on clinical cardiology, heart failure and transplantation committee; Quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and Council on epidemiology and prevention. Circulation 2006; 113: 1807-16.
14. [14] Van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121: 2169-75.
15. [15] Anderson JL, Horne BD. Birthing the genetics of peripartum cardiomyopathy. Circulation 2010; 121: 2157-9.
16. [16] Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010; 121: 2176-82.
17. [17] Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy. National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283: 1183-8.
18. [18] Baruteau AE, Leurent G, Schleich JM, Gervais R, Daubert JC, Mabo P. Can peripartum cardiomyopathy be familial? Int J Cardiol 2009; 137: 183-5.
19. [19] Bhattacharyya A, Basra SS, Sen P, Kar B. Peripartum cardiomyopathy: a review. Tex Heart Inst J 2012; 39: 8-16.
20. [20] Cooper LT, Mather PJ, Alexis JD, et al. Myocardial Recovery in Peripartum Cardiomyopathy: Prospective Comparison With Recent Onset Cardiomyopathy in Men and Nonperipartum Women. J Cardiac Fail 2012; 18: 28-33.
21. [21] Gentry MB, Dias JK, Luis A, Patel A, Thornton J, Reed LG. African-american women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol 2010; 55: 654-9.
22. [22] Fillmore SJ, Parry EH. The evolution of peripartal heart failure in Zaria. Circulation 1977; 56: 1058-61.
23. [23] Karaye KM, Henein MY. Peripartum cardiomyopathy: A review article. Int J Cardiol 2013; 164: 33-8.
24. [24] Ramaraj R, Sorrell VL. Peripartum cardiomyopathy: Causes, diagnosis, and treatment. CCJM 2009; 76: 289-96.
25. [25] Nabhan A. Peripartum cardiomyopathy. ASJOG 2005; 2: 231-7.
26. [26] Fuentes F, Sybers HD. Peripartum cardiomyopathy: the value of endomyocardial biopsy in diagnosis, prognostification, and therapy. Tex Heart Inst J 1988; 15: 55-8.
27. [27] Leurent G, Baruteau AE, Larralde A, et al. Contribution of cardiac MRI in the comprehension of peripartum cardiomyopathy pathogenesis. Int J Cardiol 2009; 132: e91-3
28. [28] Bhakta P, Biswas BK, Banerjee B. Peripartum cardiomyopathy: review of the literature. Yonsei Med J 2007; 48: 731-47.
29. [29] Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregancy and lactation. Obstet Gynecol 2008; 112: 333-40.
30. [30] Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of INFgamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008; 10: 861-8.
31. [31] Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 2007; 93: 488-90.
32. [32] Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. Int J Cardiol 2007; 118: 14-20.
33. [33] Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616-25.
34. [34] Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012; 59: 779-92.
35. [35] Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116: 2216-33.
36. [36] Bültmann BD, Klingel K, Näbauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193: 363-5.
37. [37] Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81: 922-8.
38. [38] Blauwet LA, Libhaber E, Forster O, et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 2013; 99: 308-13.
39. [39] Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol 2009; 201: 171.e1-5.
40. [40] Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 1994; 74: 474-7.
41. [41] Ntusi NBA, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol 2009; 131: 168-179.
42. [42] Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987; 18: 619-24.
43. [43] Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360: 1526-38.
44. Krejci J, Hude P, Spinarova L, et al. The variable clinical course of peripartum cardiomyopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 156: 1-6. Available Oct 31, 2012 at http://dx.doi.org/10.5507/bp.2012.080
45. [45] Kuethe F, Lindner J, Matsche K, et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clinical Infectious Diseases 2009; 49: 1660-6.
46. [46] Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with „idiopathic“left ventricular dysfunction. Circulation 2005; 111: 887-93.
47. [47] Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interoferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-8.
48. [48] Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002; 23: 301-24.
49. [49] Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27: 441-6.
50. [50] Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in peripartum cardiomyopathy of G_(q) transgenic mice. Circulation 2003; 108: 3036-41.
51. [51] Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin Dcleaved 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128: 589-600.
52. [52] Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med 2008; 18: 173-9.
53. [53] Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121: 1465-73.
54. [54] Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol 2012; 154: 27-31.
55. [55] Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333-8.
56. [56] Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123: 2143-54.
57. [57] Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet 2009; 104: 125-7.
58. [58] Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000; 35: 701-5.
59. [59] Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100: 302-4.
60. [60] Amos AM, Jaber WA, Russel SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152: 509-13.
61. [61] Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991-1997. Obstet Gynecol 2003; 102: 1326-31.
62. [62] Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Cardiac Fail 2009; 15: 645-50.
63. [63] Gevaert S, Van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and „bridge to“therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation and continuous-flow left ventricular assist devices. Crit Care 2011; 15: R93.
64. [64] Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 2008; 29: 2388-2442.
65. [65] Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999; 34: 177-180.
66. [66] McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-9.
67. [67] Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45.
68. [68] Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virusnegative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30: 1995-2002.
69. [69] Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxiphylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Hear Fail 2002; 4: 305-9.
70. [70] Fett JD. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol 2008; 51: 2083.
71. [71] Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation 2010; 121: 1463-4.
72. [72] Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant 2012; 31: 180-6.
73. [73] Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for longterm follow-up and sustained therapy. Eur J Heart Fail 2012; 14: 895-901.
74. [74] Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail 2012; 18: 21-7
75. [75] Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344: 1567-71.
76. [76] Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 2010; 109: 34-6.
77. [77] Habli M, O´Brian T, Nowack E, Khouri S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynaecol 2008; 199: 415.e1-5.